Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer

Cytotherapy

Volumn 3, Issue 2, 2001, Pages 85-95

  Preti, R A ^a,g   Lazarus, H M ^c   Winter, J ^d   Stadtmauer, E A ^e   Nadasi, S ^a   McMannis, J ^f   Karandish, S ^f   Jennis, A ^b   Goldberg, S L ^b   Pecora, A L ^a,b  

^a Progenitor Cell Therapy   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Nexell Therapeutics Inc   (United States)

^g Progenitor Cell Therapy   (United States)

Author keywords

CD34 selection; Immunomagnetic beads; Isolex; Metastatic breast cancer transplantation; Negative selection; Positive selection

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; AGED; APHERESIS; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD TRANSFUSION; BONE MARROW PURGING; BREAST CANCER; CELL COUNT; CELL POPULATION; CELL SELECTION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPLETION; DEVICE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PURIFICATION; STEM CELL; THROMBOCYTE COUNT; TRANSPORT KINETICS; TUMOR CELL DESTRUCTION;

EID: 17744389970     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240152584578     Document Type: Article

References (43)

1. Vredenburgh JJ, Silva O, Broadwater G et al. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 1997;3:91-7.
2. Passos-Coelho JL, Ross AA, Moss TJ et al. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony stimulating factor. Blood 1995; 85:1138-43.
3. Passos-Coelho J, Ross AA, Kahn DJ et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996;14: 2569-75.
4. Pecora AL, Lazarus H, Cooper B et al. Breast cancer contamination in peripheral blood stem cell collections associates with bone marrow disease and type of mobilization. Blood 1997;90(Suppl 1):abstract 434.
5. Kahn DG, Prilutskaya M, Cooper B et al. The relationship between the incidence of tumor cell contamination and number of phereses for stage IV breast cancer. Blood 1997; 90(Suppl 1):abstract 2514.
6. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-5.
7. Brenner MK, Rill DR, Moen RC. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993;341:85-6.
8. Deisseroth AB, Zu Z, Claxton D. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068-74.
9. Grande M, Barbu V, Van Den Akker J et al. Autologous bone marrow transplantation in ALL: relapse linked to infusion of tumor cells with the back-up marrow. Bone Marrow Transplant 1994;14:477-80.
10. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the harvested marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14:214-19.
11. Fields KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996;14:1868-76.
12. Brockstein BE, Ross AA, Moss TJ et al. Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. J Hematotherapy 1996;5:617-24.
13. Gluck S, Ross AA, Goldstein L et al. Detection of breast cancer cells in the apheresis product and their potential clinical significance. Blood 1996;88(Suppl 1):605a.
14. Gribben J, Freedman A, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525-31.
15. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449-57.
16. Moss TJ, Umiel T, Herzig RM et al. The presence of clono-genic breast cancer cells in peripheral blood stem cell products correlates with an extremely poor prognosis for patients with stage IV disease. Blood 1997;90(Suppl 1): abstract 4570.
17. Kemshead JT. The immunomagnetic manipulation of bone marrow. In: Gee AP, editor. Bone marrow processing and purging: A practical guide. CRC Press. 1991:293-305.
18. Kvalheim G, Wang MY, Pharo A et al. Purging of tumor cells from leucopheresis products: experimental and clinical aspects. J Hematother 1996;5:427-36.
19. + B cell precursors. Stem Cells Dayt 1994;12:95-102.
20. Mapara MY, Körner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical staining and reverse-transcriptase chain reaction. Blood 1997;89:337-43.
21. Preti RA, Nadasi S, Murawski et al. Single step positive/negative purging for breast cancer using the Isolex 300i magnetic cell separator. Blood 1997;90(Suppl 1): 4306.
22. Loudavaris M, Unverzagt K, Martinson J et al. Simultaneous positive/negative selection for T cell depletion with the Isolex 300i magnetic cell separator. Blood 1997;90(Suppl 1):1874.
23. Hardwick RA, Kulchinski D, Mansour V. Design of large-scale separation systems for positive and negative immunomagnetic selection of cells using superparamagnetic microspheres. J Hematotherapy 1992;1:386-90.
24. Sutherland DR, Keating A. The CD34 antigen: structure, biology, and potential clinical applications. J Hematotherapy 1992;1:131-42.
25. Civin CI, Strauss LC, Brovall C. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133:157.
26. Ugelstad J, Berge A, Schmidt R. New developments in production and application of monosized polymer particles. In: Reichert and Geisler, editors. Polymer reaction kinetics. Huthig & Wepf, Basel, 1986:77-86.
27. Chang M, Richards G, Rembaum A. Polyacrolein microspheres: preparation and characteristics. Methods Enzymol 1985;112:150.
28. Hansen M, Mansour V, Yacob D et al. Performance of a novel peptide CD34+ releasing agent for the Isolex system. Bone Marrow Transplant 1996;17(Suppl 1):S29.
29. Rubbi CP, Patel D, Rickwood D. Evidence of surface antigen detachment during incubation of cells with immuno- magnetic beads. J Immunol Methods 1993;166:233-41.
30. Silvestri F, Banavali S, Savignano C et al. CD34 cell selection: focus on immunomagnetic beads and chymopapain. Int J Artif Organs 1993;16(Suppl 5):96-101.
31. Stiff PJ, Koester AR, Weidner MK. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood 1987;70:974-80.
32. Lazarus HM, Andersen J, Chen MG et al. Recombinant GM-CSF after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group trial. Blood 1991;78: 830-7.
33. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematotherapy 1996;5:213-8.
34. Antman K, Ayash L, Elias A et al. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992;10:102-10.
35. Fields KK Agaliotis DP, Janssen WE et al. High dose chemotherapy and the treatment of metastatic breast cancer: Selecting the regimen and the source of stem cells. Cancer Control 1994;1:213-18.
36. Pecora AL, Lazarus HL, Stadtmauer EA et al. Effect of induction chemotherapy and tandem cycles of high dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transplant 2000; In press.
37. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000;342:1069-76.
38. Passos-Coehho J, Ross A, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 1994;54:2366-71.
39. Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12.
40. Schiller G, Vescio R, Freyetes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma. Blood 1990,86:390-7.
41. Friedman J, Lazarus HM, Koc ON. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant 2000;26:831-6.
42. Koc ON, Gerson SL, Phillips GL et al. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment. Bone Marrow Transplant 1998;20:337-43.
43. - cells influence days to engraftment and transfusion requirements in autologous blood stem cell recipients. J Clin Oncol 1998;16:2093-104.